X

Trial Profile

A Phase I Trial of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ProAgio ProDa BioTech (Primary) ; Gemcitabine
Indications Adenocarcinoma; Gastrointestinal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors ProDa BioTech

Most Recent Events

23 Apr 2024 Planned End Date changed from 1 May 2024 to 1 Feb 2025.
23 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
29 Oct 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com